07:58 AM EST, 11/27/2025 (MT Newswires) -- InnoCan Pharma ( INNPF ) said Thursday that operating loss remained relatively stable even as revenue fell 10% for the first nine months of this year.

The company reported an operating loss of US$0.33 million, a 1.5% increase from the $0.32 million last year.

Revenue dropped to $21.6 million, over the same period.

The company, which develops drug delivery platform technologies, confirmed it is progressing toward a U.S. public offering.

"We developed and implemented a strategic response to tariffs and optimized our supply chain, resulting in substantial cost savings and improved gross profit performance. This positions the Company well for outperformance as the market recovers," said chief operating officer Roni Kamhi.